Astrazeneca

FromAstraZeneca ([email protected])
Subject (50)Ultomiris NMOSD Ph. III trial met primary endpoint
Preheader (118)Ultomiris met primary endpoint in CHAMPION-NMOSD Phase III trial in adults with neuromyelitis optica spectrum disorder
Typography
Arial
Colors
Text Analysis
Body Words172
Subject Words8
Body Emojis1
Subject Emojis
Media Analysis
Text Links8
Image Links4
Total Links12
Images7
Technical Metrics
Performance
HTML Size, Kb
Pixel Length, px
X-Spam Score0.4
Preheader OptimizedNo
Timing
Day of WeekMonday
TimeEvening

Ultomiris NMOSD Ph. III trial met primary endpoint

Ultomiris met primary endpoint in CHAMPION-NMOSD Phase III trial in adults with neuromyelitis optica spectrum disorder
Ultomiris NMOSD Ph. III trial met primary endpoint